BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Thoralf Lange et al.|Cancer Cell|2014Cited by 366
Concurrent <i>CDX2 cis</i>-deregulation and <i>UBTF::ATXN7L3</i> fusion define a novel high-risk subtype of B-cell ALLMarie Passet, Emmanuelle Clappier, Rathana Kim et al.|Blood|2022Cited by 34
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Thibaut Leguay, Marc Delord et al.|Journal of Clinical Oncology|2024Cited by 33
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i> -Mutant Clonal HematopoiesisRathana Kim, Emmanuelle Clappier, Hugo Bergugnat et al.|Blood Cancer Discovery|2023Cited by 33
Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO StudyPatrice Chevallier, Philippe Rousselot, Thibault Leguay et al.|Blood|2022Cited by 32